Is Krystal Biotech (KRYS) overvalued or fairly valued?

MarketChacha shows Krystal Biotech's valuation in context — a trailing P/E of about 48.4, a forward P/E of about 34.2, a price-to-book of about 7.8 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Krystal Biotech's revenue?

Krystal Biotech reported revenue of $389.1M for FY2025, with net profit of $204.8M, per official filings.

What is the share price of Krystal Biotech (KRYS)?

Krystal Biotech last traded at $337.77 (-0.4% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Krystal Biotech

KRYS · NYSE · Healthcare · United States

$337.77-0.4%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 7:35 PM

Snapshot

TickerKRYS

ExchangeNYSE

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees295

HeadquartersPittsburgh, United States

Market cap$10.0B

P/E (TTM)48.4

P/B7.8

Volume195.88K

Websitewww.krystalbio.com

Filings tracked4

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Profile as reported by Yahoo Finance.

Who owns it

Insiders11.0%
Institutions89.0%
Public & other0.0%

513 institutional holders

As reported by Yahoo Finance.

Top holders

FMR, LLC14.84%
Blackrock Inc.13.37%
Avoro Capital Advisors LLC9.80%
Vanguard Portfolio Management LLC4.94%
State Street Corporation4.46%
Vanguard Capital Management LLC3.95%
Soleus Capital Management, L.P.3.91%
Capital World Investors2.80%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

Forensic scorecard

Over 3 years only 0.77× of reported profit became operating cash — the classic sign that headline earnings may be running ahead of the cash actually generated. Often explained by working capital funding growth; worth a closer look.

Cash conversion0.77×

Net margin trend21.6% → 52.6%

Margin has expanded by about 31.1 points — the business is getting more profitable.

Return on equity16.8%

Latest ROE of 16.8% — capital is generating a healthy return.

Growth qualityrev 177% · PAT 333%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $134.7M · EPS 2.16

Est. earnings growth -18.7%

Next fiscal year

Rev $670.2M · EPS 9.87

Est. earnings growth +20.3%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$130.5052-wk range$382.54

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Market cap

$10.0B

Day change

-0.4%

P/E (TTM)

48.4

Fwd P/E

34.2

P/B

7.8

Beta

0.50

Revenue (FY2025)

$389.1M

Net margin

52.6%

ROE

16.8%

Revenue CAGR (2y)

+177.0%

Profit CAGR (2y)

+332.9%

EPS (FY2025)

6.84

Net profit (FY2025)

$204.8M

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about KRYS

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$389.1M	$204.8M	6.84	52.6%	16.8%
FY2024	$290.5M	$89.2M	3.00	30.7%	9.4%
FY2023	$50.7M	$10.9M	0.39	21.6%	1.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	$116.4M	$55.9M	1.83	48.1%
2025Q3	$97.8M	$79.4M*	2.66	—
2025Q2	$96.0M	$38.3M	1.29	39.9%
2025Q1	$88.2M	$35.7M	1.20	40.5%
2024Q3	$83.8M	$27.2M	0.91	32.4%
2024Q2	$70.3M	$15.6M	0.53	22.2%
2024Q1	$45.3M	$932,000	0.03	2.1%
2023Q3	$8.6M	$80.7M*	2.79	—
2023Q2	$0	$-33.2M	-1.25	—
2023Q1	$0	$-45.3M	-1.76	—

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Other events, Exhibits
SEC7/21/2026material
8-K — Shareholder vote results
SEC5/20/2026material
10-Q filing
SEC5/4/2026
8-K — Exhibits
SEC5/4/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.